1-20 of 46
Tibor Kovacsovics
Close
Save search
Follow your search
Access your saved searches in your account
Would you like to receive an alert when new items match your search?
Close Modal
Sort by
Journal Articles

Updated Results and Longer Follow-up from the AUGMENT-101 Phase 2 Study of Revumenib in All Patients with Relapsed or Refractory (R/R) KMT2Ar Acute Leukemia

Ibrahim Aldoss, Ghayas C. Issa, James S. Blachly, Michael J. Thirman, Gabriel N Mannis, Martha L. Arellano, John F. DiPersio, Elie Traer, C. Michel Zwaan, Neerav Shukla, Branko Cuglievan, Carolyn S. Grove, Matthew Greenwood, Christine M. McMahon, Alexander E. Perl, Richard M. Stone, Cristina Papayannidis, David S. Dickens, Maël Heiblig, Andrius Žučenka, Pau Montesinos, Ioannis Mantzaris, Tibor Kovacsovics, Paul J. Shami, Li Yu, Rebecca G. Bagley, Nicole McNeer, Eytan M. Stein
Journal: Blood
Blood (2024) 144 (Supplement 1): 211.
https://doi.org/10.1182/blood-2024-194384
Published: 2024
Journal Articles

Efficacy and Safety of Uproleselan Combined with Chemotherapy Vs. Chemotherapy Alone in Relapsed/Refractory Acute Myeloid Leukemia: Findings from an International Phase 3 Trial

Daniel J. DeAngelo, Andre C. Schuh, Brian A. Jonas, Pamela S. Becker, Anjali S. Advani, Geoffrey L. Uy, Janusz Krawczyk, Harry P. Erba, Gabriel N Mannis, Chun Yew Fong, Florian Kuchenbauer, Mary-Elizabeth M. Percival, Jane L. Liesveld, William Blum, Brenda W Cooper, Alice Mims, Francesco Lanza, Jeroen J.W.M. Janssen, Juan Miguel Bergua Burgues, Tibor Kovacsovics, Norbert Vey, Martina V. Hemmer, Gaetano Bonifacio, Edwin Rock, Pau Montesinos
Journal: Blood
Blood (2024) 144 (Supplement 1): 733.
https://doi.org/10.1182/blood-2024-209097
Published: 2024
Journal Articles

Entospletinib (ENTO) in Combination with Cytarabine (Ara-C) and Daunorubicin (DNR) in Newly Diagnosed (ND) Adult Patients with NPM1 -Mutated and FLT3 -ITD Wild-Type Acute Myeloid Leukemia (AML) Is Associated with Good Response and Survival: A Phase 2 Sub-Study of the Beat AML Master Trial

Uma Borate, Rui Li, Ying Huang, Ronan T. Swords, Elie Traer, Eytan Stein, James M. Foran, Maria R. Baer, Vu H. Duong, Wendy Stock, Olatoyosi Odenike, Prapti Patel, Robert H. Collins, Yazan F. Madanat, Tibor Kovacsovics, Michael W. Deininger, Catherine Smith, Rebecca L. Olin, Martha L. Arellano, William G. Blum, Gary J. Schiller, Tara L. Lin, Matthew C. Foster, Michael M. Boyiadzis, Robert L. Redner, Zeina Al-Mansour, Emily K Curran, Nyla A. Heerema, Theophilus J Gana, Molly Martycz, Leonard Rosenberg, Sonja Marcus, Ashley O. Yocum, Timothy Chen, Mona Stefanos, Franchesca Druggan, Amy Burd, Ross L. Levine, Brian J. Druker, John C. Byrd, Alice S. Mims
Journal: Blood
Blood (2022) 140 (Supplement 1): 6200–6203.
https://doi.org/10.1182/blood-2022-167316
Published: 2022
Journal Articles

Treatments and Outcomes for Patients at Academic Cancer Centers with Myelodysplastic Syndrome (MDS) By Revised International Prognostic Scoring System (IPSS-R) Scores

Connor Willis, David A. Sallman, Malinda Tan, Madeline Brendle, Vonetta L. Williams, Craig Comperatore, Trang Au, Srinivas K. Tantravahi, Najla Al Ali, Jeffrey A. Gilreath, Tibor Kovacsovics, Xiting Cao, Islam Sadek, Rami S. Komrokji, David Stenehjem
Journal: Blood
Blood (2022) 140 (Supplement 1): 5291–5292.
https://doi.org/10.1182/blood-2022-162622
Published: 2022
Journal Articles

Development of a Comprehensive Program for Evaluation of Hereditary Predisposition to Hematologic Malignancies

Jennie Vagher, Bryan D. Huber, Luke Maese, Archana M Agarwal, Afaf Osman, Ami B. Patel, Tsewang Tashi, Paul J Shami, Tibor Kovacsovics, Julie D. Asch, Charles J. Parker, Srinivas K. Tantravahi
Journal: Blood
Blood (2022) 140 (Supplement 1): 11468–11470.
https://doi.org/10.1182/blood-2022-170000
Published: 2022
Journal Articles

Assessment of Midostaurin in Combination with Idarubicin-Based Induction Treatment in Acute Myeloid Leukemia

Julia Lee, Charlotte B Wagner, Stacy Prelewicz, Heena P Kurish, Rob Walchack, Danielle Cenin, Seema Patel, Mimi Lo, Danielle Schlafer, Belinda KT Li, R Donald Harvey, Bestis Wasef, Jian Ying, Tibor Kovacsovics
Journal: Blood
Blood (2022) 140 (Supplement 1): 3242–3243.
https://doi.org/10.1182/blood-2022-170123
Published: 2022
Journal Articles

A Multi-Center Phase Ib Trial of the Histone Deactylase Inhibitor (HDACi) Entinostat in Combination with Anti-PD1 Antibody Pembrolizumab in Patients with Refractory/Relapsed Myelodysplastic Syndromes (RR-MDS) or Oligoblastic Acute Myeloid Leukemia (RR-AML) after Hypomethylating Agent (HMA) Failure

Jan Philipp Bewersdorf, Rory Michael Shallis, Elad Sharon, Anne Caldwell, Wei Wei, Abdulraheem Yacoub, Yazan F. Madanat, Joshua F. Zeidner, Jessica K. Altman, Olatoyosi Odenike, Swaroopa Yerrabothala, Tibor Kovacsovics, Nikolai A. Podoltsev, Stephanie Halene, Richard F. Little, Richard Piekarz, Steven D. Gore, Tae Kon Kim, Amer M. Zeidan
Journal: Blood
Blood (2022) 140 (Supplement 1): 9084–9086.
https://doi.org/10.1182/blood-2022-158626
Published: 2022
Journal Articles

A Phase 1b Dose Escalation and Expansion Study of SNDX-5613, Azacitidine (AZA) and Venetoclax (VEN) in Newly Diagnosed, Patients ≥ 60 Years with Untreated NPM1 -Mutated/ FLT3 -Wild Type AML or KMT2A -Rearranged Acute Myeloid Leukemia (AML)

Joshua F. Zeidner, Matthew C. Foster, Mary Johnson, Ying Huang, Ronan T. Swords, Eytan Stein, James M. Foran, Maria R. Baer, Wendy Stock, Yazan F. Madanat, Tibor Kovacsovics, Rebecca L. Olin, William G. Blum, Gary J. Schiller, Tara L. Lin, Robert L. Redner, Zeina Al-Mansour, Emily K Curran, Nyla A. Heerema, Molly Martycz, Leonard Rosenberg, Sonja Marcus, Ashley O. Yocum, Timothy Chen, Mona Stefanos, Franchesca Druggan, Amy Burd, Ross L. Levine, Brian J. Druker, Uma Borate, John C. Byrd, Alice S. Mims
Journal: Blood
Blood (2022) 140 (Supplement 1): 9070–9073.
https://doi.org/10.1182/blood-2022-166715
Published: 2022
Journal Articles

A Risk-Adapted Study to Assess the Efficacy of Enasidenib and Subsequent Response-Driven Addition of Azacitidine for Newly Diagnosed IDH2 -Mutant AML Patients: 3-Year Follow-up

Eytan Stein, Sheng F Cai, Ying Huang, Andrew Dunbar, Maria R. Baer, Wendy Stock, Tibor Kovacsovics, William G. Blum, Gary J. Schiller, Rebecca L. Olin, James M. Foran, Mark R. Litzow, Tara L. Lin, Prapti A. Patel, Matthew C. Foster, Michael M. Boyiadzis, Robert H. Collins, Jordan Chervin, Abigail B. Shoben, Jo-Anne Vergilio, Nyla A. Heerema, Leonard Rosenberg, Timothy Chen, Ashley O. Yocum, Franchesca Druggan, Sonja Marcus, Mona Stefanos, Molly Martycz, Brian J. Druker, Alice S. Mims, Uma Borate, Amy Burd, John C. Byrd, Ross L. Levine
Journal: Blood
Blood (2022) 140 (Supplement 1): 2016–2019.
https://doi.org/10.1182/blood-2022-166850
Published: 2022
Journal Articles

The genetic landscape of germline DDX41 variants predisposing to myeloid neoplasms

Peng Li, Sara Brown, Margaret Williams, Thomas White, Wei Xie, Wei Cui, Deniz Peker, Li Lei, Christian A. Kunder, Huan-You Wang, Sarah S. Murray, Jennie Vagher, Tibor Kovacsovics, Jay L. Patel
Journal: Blood
Blood (2022) 140 (7): 716–755.
https://doi.org/10.1182/blood.2021015135
Published: 2022
Includes: Supplemental data
Journal Articles

Ivosidenib (IVO) in Combination with Azacitidine (AZA) in Newly Diagnosed (ND) Older Patients with IDH1 R132-Mutated Acute Myeloid Leukemia (AML) Induces High Response Rates: A Phase 2 Sub-Study of the Beat AML Master Trial

Prapti Patel, Amy S. Ruppert, Uma Borate, Eytan M. Stein, Maria R. Baer, Wendy Stock, Tibor Kovacsovics, William Blum, Martha L. Arellano, Gary J. Schiller, Rebecca L. Olin, James M. Foran, Mark R. Litzow, Tara L. Lin, Matthew C. Foster, Robert L. Redner, Zeina Al-Mansour, Christopher R. Cogle, Michael M. Boyiadzis, Ronan Swords, Robert H. Collins, Jo-Anne Vergilio, Nyla A. Heerema, Leonard Rosenberg, Ashley Owen Yocum, Sonja Marcus, Timothy Chen, Franchesca Druggan, Mona Stefanos, Theophilus J Gana, Abigail B. Shoben, Brian J. Druker, Amy Burd, John C. Byrd, Ross L. Levine, Alice S. Mims
Journal: Blood
Blood (2021) 138 (Supplement 1): 875.
https://doi.org/10.1182/blood-2021-149115
Published: 2021
Journal Articles

Gilteritinib (GILT) Monotherapy with Addition of Decitabine (DEC) in Non-Responders in Older Newly Diagnosed (ND) FLT3 Mutated Acute Myeloid Leukemia (AML) Patients Having High and Low Variant Allele Frequency (VAF): A Phase 2/1b Sub-Study of the Beat AML Master Trial

Elie Traer, Ying Huang, Alice S. Mims, Eytan M. Stein, Maria R. Baer, Wendy Stock, Tibor Kovacsovics, William Blum, Martha L. Arellano, Gary J. Schiller, Rebecca L. Olin, James M. Foran, Mark R. Litzow, Tara L. Lin, Prapti Patel, Matthew C. Foster, Robert L. Redner, Zeina Al-Mansour, Christopher R. Cogle, Michael M. Boyiadzis, Ronan Swords, Robert H. Collins, Jo-Anne Vergilio, Nyla A. Heerema, Leonard Rosenberg, Ashley O. Yocum, Sonja Marcus, Timothy Chen, Franchesca Druggan, Mona Stefanos, Theophilus J Gana, Abigail B. Shoben, Brian J. Druker, Amy Burd, John C. Byrd, Ross L. Levine, Uma Borate
Journal: Blood
Blood (2021) 138 (Supplement 1): 1277.
https://doi.org/10.1182/blood-2021-148207
Published: 2021
Journal Articles

Entospletinib (ENTO) and Decitabine (DEC) Combination Therapy in Older Newly Diagnosed (ND) Acute Myeloid Leukemia (AML) Patients with Mutant TP53 or Complex Karyotype Is Associated with Poor Response and Survival: A Phase 2 Sub-Study of the Beat AML Master Trial

Vu H. Duong, Amy S. Ruppert, Alice S. Mims, Uma Borate, Eytan M. Stein, Maria R. Baer, Wendy Stock, Tibor Kovacsovics, William G. Blum, Martha L. Arellano, Gary J. Schiller, Rebecca L. Olin, James M. Foran, Mark R. Litzow, Tara L. Lin, Prapti A. Patel, Matthew C. Foster, Robert L. Redner, Zeina Al-Mansour, Christopher R. Cogle, Ronan T. Swords, Robert H. Collins, Jo-Anne Vergilio, Nyla A. Heerema, Leonard Rosenberg, Ashley O. Yocum, Sonja Marcus, Timothy Chen, Franchesca Druggan, Mona Stefanos, Theophilus J Gana, Abigail B. Shoben, Brian J. Druker, Amy Burd, John C. Byrd, Ross L. Levine, Michael M. Boyiadzis
Journal: Blood
Blood (2021) 138 (Supplement 1): 1279.
https://doi.org/10.1182/blood-2021-151234
Published: 2021
Journal Articles

A Phase 2 Multi-Arm Study of Magrolimab Combinations in Patients with Relapsed/Refractory Multiple Myeloma

Barry Paul, Michaela Liedtke, Jorge Monge, Maria Chaudhry, Robert M. Rifkin, Mitul D. Gandhi, Jack Khouri, Andrew Kin, Tibor Kovacsovics, Moshe Y. Levy, Ann Mohrbacher, William Schmidt, David S. Siegel, Rebecca W. Silbermann, Anna Louise Byrne, Tina Ncube, Michael Murphy, Lin Gu, Nishanthan Rajakumaraswamy, Mark Chao, Saad Z. Usmani
Journal: Blood
Blood (2021) 138 (Supplement 1): 2757.
https://doi.org/10.1182/blood-2021-145903
Published: 2021
Journal Articles

Disease Characteristics of AML Patients with Germline DDX41 Variants

Jennie Vagher, Shobi Venkatachalam, Peng Li, Julie D. Asch, Bryan D. Huber, Tsewang Tashi, Paul J Shami, Tibor Kovacsovics, Luke Maese, Charles J. Parker, Srinivas K. Tantravahi
Journal: Blood
Blood (2021) 138 (Supplement 1): 3384.
https://doi.org/10.1182/blood-2021-154117
Published: 2021
Journal Articles

CYP3A inhibitors and impact of these agents on outcomes in patients with acute myeloid leukemia treated with venetoclax plus azacitidine on the VIALE-A study

Brian A Jonas, MD PhD, Courtney D. Dinardo, MDMSc, Nicola Fracchiolla, Alexander Pristupa, MD, Kenichi Ishizawa, MD PhD, Jie Jin, MD PhD, Marina Konopleva, MD PhD, Yishai Ofran, Pau Montesinos, MD PhD, Tibor Kovacsovics, MD, Jun-Ho Jang, MD, Hagop M. Kantarjian, MD, Wan-Jen Hong, MD, Yinghui Duan, PhD, William Ainsworth, Jalaja Potluri, MD, Michael Werner, Anders Erik Svensson, MD, Keith W. Pratz, MD
Journal: Blood
Blood (2020) 136 (Supplement 1): 50–52.
https://doi.org/10.1182/blood-2020-134850
Published: 2020
Journal Articles

Enasidenib (ENA) Monotherapy with Addition of Azacitidine in Non-Responders Is Effective in Older Patients with Newly Diagnosed IDH2 Mutated Acute Myeloid Leukemia (AML): A Completed Phase 2/1b Sub-Study of the Beat AML Master Trial

Eytan M. Stein, MD, Ying Huang, MS, MA, Uma Borate, Maria R. Baer, MD, Wendy Stock, MD, Tibor Kovacsovics, MD, William Blum, MD, Gary J. Schiller, MD, Rebecca L. Olin, MD, James M. Foran, MD, Mark Litzow, MD, Tara Lin, MD, Prapti A. Patel, MD, Matthew C Foster, MD, Michael Boyiadzis, MD, Robert H. Collins, MD, Jo-Anne Vergilio, MD, Nyla A Heerema, PhD, Leonard Rosenberg, Ashley Owen Yocum, PhD, Timothy Chen, PhD, Franchesca Druggan, MSc, Sonja Marcus, MPH, Mona Stefanos, MBChB, Jordan Chervin, Abigail Shoben, Brian J. Druker, MD, Amy Burd, PhD, John C. Byrd, MD, Ross L. Levine, MD, Alice S. Mims, MD
Journal: Blood
Blood (2020) 136 (Supplement 1): 27–30.
https://doi.org/10.1182/blood-2020-143265
Published: 2020
Journal Articles

Daratumumab plus CyBorD for patients with newly diagnosed AL amyloidosis: safety run-in results of ANDROMEDA

Clinical Trials & Observations
Giovanni Palladini, Efstathios Kastritis, Mathew S. Maurer, Jeffrey Zonder, Monique C. Minnema, Ashutosh D. Wechalekar, Arnaud Jaccard, Hans C. Lee, Naresh Bumma, Jonathan L. Kaufman, Eva Medvedova, Tibor Kovacsovics, Michael Rosenzweig, Vaishali Sanchorawala, Xiang Qin, Sandra Y. Vasey, Brendan M. Weiss, Jessica Vermeulen, Giampaolo Merlini, Raymond L. Comenzo
Journal: Blood
Blood (2020) 136 (1): 71–80.
https://doi.org/10.1182/blood.2019004460
Published: 2020
Includes: Supplemental data
Journal Articles

Newly Diagnosed AML Patient Samples Demonstrate High Degree of Concordance in Identification of Pathogenic Mutations By Next Generation Sequencing (NGS) Performed at Enrolling Institutions Compared to Central Laboratory Results in the Beat AML Master Trial

Uma Borate, MD, Amy S. Ruppert, MAS, PhD, Fei Yang, MD, Dan Jones, MD PhD, Sean Caruthers, Weiqiang Zhao, MD PhD, Jo-Anne Vergilio, MD, Amy Burd, PhD, Dean Pavlick, Luke Juckett, BSc, BA, MSc, Eytan M. Stein, MD, Prapti A. Patel, MD, Maria R. Baer, MD, Wendy Stock, MD, Gary J. Schiller, MD, William Blum, MD, Tibor Kovacsovics, MD, Mark Litzow, MD, James M. Foran, MD, Nyla A. Heerema, PhD, Leonard Rosenberg, Sonja Marcus, MPH, Ashley Owen Yocum, PhD, Mona Stefanos, MBChB, Brian J. Druker, John C. Byrd, MD, Ross L. Levine, MD, Alice S. Mims, MD
Journal: Blood
Blood (2019) 134 (Supplement_1): 2145.
https://doi.org/10.1182/blood-2019-131253
Published: 2019
Journal Articles

A Phase 1b Study of Glasdegib in Combination with Azacitidine in Patients with Untreated Higher-Risk Myelodysplastic Syndromes, Acute Myeloid Leukemia, and Chronic Myelomonocytic Leukemia

Mikkael A. Sekeres, MD MS, Michael W. Schuster, MD, Magalie Joris, MD, Jürgen Krauter, MD, Johan A. Maertens, MD PhD, Emmanuel Gyan, MD PhD, Tibor Kovacsovics, MD, Amit Verma, MBBS, Paresh Vyas, MD PhD, Eunice S. Wang, MD, Weidong Wendy Ma, Mirjana Zeremski, MD, Arthur Kudla, Geoffrey Chan, MD, Amer M. Zeidan, MBBS, MHS
Journal: Blood
Blood (2019) 134 (Supplement_1): 177.
https://doi.org/10.1182/blood-2019-124050
Published: 2019